

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



友芝友生物製藥

WUHAN YZY BIOPHARMA CO., LTD.

武漢友芝友生物製藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2496)

Date of Board Meeting

The board of directors (the “**Board**”) of Wuhan YZY Biopharma Co., Ltd. (the “**Company**”) hereby announces that a meeting of the Board of the Company will be held on Thursday, 28 September 2023 for the purpose of, among other matters, considering and approving the interim report of the Company and its subsidiaries for the six months ended 30 June 2023 and its publication, considering recommendation on payment of an interim dividend (if any), and transacting other business.

By order of the Board

Wuhan YZY Biopharma Co., Ltd.

Dr. Zhou Pengfei

Chairman and Executive Director

Hong Kong, 25 September 2023

As at the date of this announcement, the board of directors of the Company comprises Dr. Zhou Pengfei as executive director, Mr. Yuan Qian, Dr. Zhou Hongfeng, Mr. Pang Zhenhai, Dr. Hui Xiwu, Ms. Liang Qian, Dr. Liu Dan, Dr. Guo Hongwei and Mr. Xie Shouwu as non-executive directors; and Dr. Cheng Bin, Dr. Dai Weiguo, Ms. Fu Lili, Dr. Deng Yuezhen and Dr. Chen Bin as independent non-executive directors.